Skip to content
Pharma Observatory a Scientist.com platform

Source-defined biomarker

Circulating tumor DNA (ctDNA) molecular residual disease (MRD)

This exact source name has not been reconciled to a broader biomarker identity.

Circulating tumor DNA (ctDNA) molecular residual disease (MRD) is a source-defined biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), each linked to its source.

Source-scoped identity
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions 1recorded FDA biomarker qualification projects Measured, none recorded Assay-provider ledger Measured, none recorded

FDA companion diagnostic

An FDA-cleared or approved companion diagnostic names this biomarker.

Get the Circulating tumor DNA (ctDNA) molecular residual disease (MRD) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Source-level evidence only

Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.

FDA companion diagnostic assertions (1)

Shown in this order: most recent decision first.

FDA companion diagnostic assertions
Diagnostic Source biomarker wording Manufacturer Indication Decision date
Signatera CDx Circulating tumor DNA (ctDNA) molecular residual disease (MRD) Natera, Inc. Muscle Invasive Bladder Cancer (MIBC) 2026-05-15

Not on this page

Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.

Browse all biomarker evidence pages